Listed

Edwards Lifesciences Corp: Form 10-K for the period ended Dec 31, 2020

Filed with the SEC on Feb 12, 2021 and accepted by EDGAR at Feb 12, 2021, 16:58 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-10-01 to 2020-12-31$1.19bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue12 months2020-01-01 to 2020-12-31$4.39bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2020-01-01 to 2020-12-31$1.08bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2020-10-01 to 2020-12-31$895.4mus-gaap:GrossProfit
Gross profit12 months2020-01-01 to 2020-12-31$3.31bnus-gaap:GrossProfit
Research and development12 months2020-01-01 to 2020-12-31$760.7mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2020-01-01 to 2020-12-31$1.23bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2020-01-01 to 2020-12-31$897.6mus-gaap:OperatingIncomeLoss
Interest expense12 months2020-01-01 to 2020-12-31$15.8mus-gaap:InterestExpense
Income tax12 months2020-01-01 to 2020-12-31$93.3mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-10-01 to 2020-12-31$309.5mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income12 months2020-01-01 to 2020-12-31$823.4mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2020-10-01 to 2020-12-31$0.49us-gaap:EarningsPerShareDiluted
Diluted EPS12 months2020-01-01 to 2020-12-31$1.30us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-10-01 to 2020-12-31$0.50us-gaap:EarningsPerShareBasic
Basic EPS12 months2020-01-01 to 2020-12-31$1.32us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2020-01-01 to 2020-12-31631,900,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2020-01-01 to 2020-12-31$1.05bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2020-01-01 to 2020-12-31$407.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases12 months2020-01-01 to 2020-12-31$625.4mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-12-31$1.18bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-12-31$3.09bnus-gaap:AssetsCurrent
Total assetsAt period end2020-12-31$7.24bnus-gaap:Assets
Current liabilitiesAt period end2020-12-31$893.9mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2020-12-31$595.0mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2020-12-31$4.57bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001099800-21-000007. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.